$PFE · PFIZER INC SEC Filings
Position Tracker tracks 13 SEC EDGAR filings for PFIZER INC ($PFE) from August 5, 2026 through November 3, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 2 Form 8-K current event disclosures, and 8 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$PFE 8-K — PFIZER INC
Ending CFO uncertainty at a $171B pharma company matters, but the internal promotion signals continuity rather than a strategic overhaul.
$PFE 10-Q — PFIZER INC
A 40% nine-month profit collapse at a $175B pharma giant, driven by a doubling of opaque "other deductions," demands investor attention on what's buried in that line.
$PFE 8-K — PFIZER INC
Pfizer's guidance raise and 32% operational growth in new products demonstrate the post-COVID portfolio transition is gaining traction, with non-COVID revenue now growing 7% org…
$PFE 4 — Pfizer Inc.
Pfizer filed a Form 4 reporting a change in beneficial ownership for Albert Bourla, the company’s Chairman and CEO. The filing states that on September 15, 2026, Bourla acquired…
$PFE 4 — Pfizer Inc.
Pfizer Inc. filed a Form 4 on September 1, 2026, reporting a transaction by Albert Bourla, the company's Chairman and CEO. On August 31, 2026, Bourla acquired 21 phantom stock u…
$PFE N-PX — Pfizer Inc.
Pfizer Inc. filed a Form N-PX annual report of proxy voting record with the SEC on August 31, 2026. The filing covers the reporting period ended June 30, 2026. Pfizer identifies…
$PFE 3 — Pfizer Inc.
Pfizer Inc. filed a SEC Form 3 on August 28, 2026, reporting the initial beneficial ownership of Cecile Guegan, an Executive Vice President of the company, as of August 17, 2026…
$PFE 4 — Pfizer Inc.
Pfizer Inc. filed a Form 4 on August 17, 2026, reporting a change in beneficial ownership for Albert Bourla, the company’s Chairman and CEO. The filing states that on August 14,…
$PFE 13F-HR — Pfizer Inc.
Pfizer Inc. filed a Form 13F-HR with the Securities and Exchange Commission on August 13, 2026. This is a quarterly institutional investment manager report that discloses Pfizer…
$PFE 4 — Pfizer Inc.
A Form 4 was filed with the SEC on August 12, 2026, reporting a change in beneficial ownership for Albert Bourla, Pfizer Inc.’s Chairman and CEO. The filing discloses that Bourl…
$PFE 4 — Pfizer Inc.
This SEC Form 4 reports a change in beneficial ownership for Jennifer B. Damico, Pfizer Inc.’s Senior Vice President and Controller. According to the filing, she sold 3,278 shar…
$PFE 4 — Pfizer Inc.
A Form 4 filing from Pfizer Inc. reports that Ronald E. Blaylock, a director of the company, acquired 39,231 shares of Pfizer common stock on August 5, 2026, at a price of $25.4…
$PFE 4 — Pfizer Inc.
A Form 4 filing submitted on August 5, 2026, reports that Mortimer J. Buckley, a director of Pfizer Inc., acquired shares of Pfizer common stock. The transaction was a purchase…